Stroke
Conditions
Keywords
stroke, Rehabilitation, WalkAide (WA), Functional Electrical Stimulation (FES)
Brief summary
Among the sequelae of stroke, gait disorder is directly linked to the degree of autonomy in the daily life of patients. It is considered significant effects on their Quality of Life(QOL). Further methods of rehabilitation are required for convalescent patients to recover their function soon and better, due to a multitudes of recovery patient with troubles such as gait problem. This trial is studying to investigate the effects of gait training with a functional electrical stimulation (FES) 'WalkAide\[R\](WA)' to improve the lower-limb function and ambulation in convalescent stroke patients.
Detailed description
This study is targeting convalescent patients within 6 months after the onset of initial stroke (cerebral infarction or cerebral hemorrhage) and also observing the foot drop during walking. Some study for the patients after the onset of stroke (over several months) are reported that a case of the efficacy by the treatment using the FES, and another case of using FES indicated the equal efficacy and the higher QOL compared to using ankle-foot orthosis(AFO). However, these are clinical research results overseas and there are not so many studies targeting only for convalescent stroke patients. FES which recover the lost function by paralysis using electrical stimulation is recommended as convalescent rehabilitation by Japanese Guidelines for the Management of Stroke 2015 etc.. The purpose of FES treatment is the electrical stimulation to peroneal nerve of patients with foot drop and equinus foot due to central nervous system damage and the objective efficacy is following: * To improve the walking by dorsiflexing the foot during swing phase * To prevention and suppression of disuse atrophy * To increase local blood flow * To re-educate muscle * To maintain or increase the range of joint motion
Interventions
DEVICEWA group
Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
OTHERControl
Conventional rehabilitation therapy and gait training without WA.
Sponsors
Nippon Medical School
Kagoshima University
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* 1\) Patients who agree to participate in this study and provide their informed consent * 2\) Patients from 20 to 85 years old at the time of consent * 3\) Patients of convalescent stoke (within 6 months of onset) * 4\) Patients with a first episode of stroke, which type limited intracranial hemorrhage or ischemic stroke (excluding subarachnoid hemorrhage) * 5\) Patients inpatients for the rehabilitation therapy * 6\) Patients diagnosed 3 or 4 on Functional Ambulation Classification (FAC) * 7\) Patients stable general condition(blood pressure, pulse, blood glucose level etc.) * 8\) Patients with drop foot in walking
Exclusion criteria
* 1\) Patients due to severe heart disease * 2\) Patients with previous gait disability, such as neurological disease * 3\) Patients with previous orthopedic disease, such as knee osteoarthritis * 4\) Patients with severe hepatic or renal dysfunction * 5\) Patients with severe sensory disturbance or severe ataxia or severe higher brain dysfunction * 6\) Patients correspond to contraindicated for the electrical stimulation (e.g. patients with a medical implant or implantable medical electrical equipment such as a cardiac pacemaker) * 7\) Patients with severe skin disease * 8\) Patients with any dose adjustment of antispasticity drugs (tizanidine hydrochloride, eperisone hydrochloride, baclofen, etc.) within 1month * 9\) Patients whose impairment severities changed during the study period * 10\) Patients taking the botulinum toxin formulation injection or the nerve block injection with phenol within 6months * 11\) Patients with any lower limb treatment using FES or the robot suit within 1month * 12\) Patients diagnosed not to use during the the WA trial operation period * 13\) Patients who do not complete the WA trial operation for 7 days * 14\) Patients joining any other clinical trials or studies with intervention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum walking distance of 6 Minute Walk Test (bare feet) | 8weeks | Measuring maximum walking distance of 6 Minute Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting for all patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| maximum walking distance of 6 Minute Walk Test (with AFO) | 8weeks | Measuring maximum walking distance of 6 Minute Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting only for patients using AFO before starting this study. |
| walking speed of 10 Meter Walk Test (bare feet) | 8weeks | Measuring maximum walking speed of 10 Meter Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting for all patients. |
| walking speed of 10 Meter Walk Test (with WA) | 8weeks | Measuring maximum walking speed of 10 Meter Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting only for WA group. |
| walking speed of 10 Meter Walk Test (with AFO) | 8weeks | Measuring maximum walking speed of 10 Meter Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting only for patients using AFO before starting this study. |
| Fugl-Meyer assessment (FMA) | 8weeks | Calculating difference of the total score of lower extremity subscale of the Fugl-Meyer Assessment (perfect score: 34 points) at baseline and after 8-weeks intervention. |
| modified Ashworth scale (MAS) | 8weeks | Calculating difference of the muscle tone six levels ( 0 , 1 , 1+ , 2 , 3 , 4 ) at baseline and after 8-weeks intervention. |
| range of motion | 8weeks | Calculating difference of the angle of the ankle succumbed back (5 ° increments) at baseline and after 8-weeks intervention. |
| maximum walking distance of 6 Minute Walk Test (with WA) | 8weeks | Measuring maximum walking distance of 6 Minute Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting only for WA group. |
| Timed up and go test (with AFO) | 8weeks | Measuring the time that patients take to rise from a chair, walk three metres, turn around, walk back to the chair, and sit down . Calculating difference of those measured values between at baseline and after 8-weeks intervention. Targeting only for patients using AFO before starting this study. |
| Timed up and go test (with WA) | 8weeks | Measuring the time that patients take to rise from a chair, walk three metres, turn around, walk back to the chair, and sit down . Calculating difference of those measured values between at baseline and after 8-weeks intervention. Targeting only for WA group. |
| Stroke Impact Scale (SIS) | 8weeks | An evaluation of summation score of the total score and physical domain (sixth domain) score. Calculating difference of those measured values between at baseline and after 8-weeks intervention. |
| Patient reported outcome measure (PRO) | 8weeks | Evaluation gait analysis using visual analogue scale(VAS scale) by Patient's own. Calculating the difference of these VAS scale between at baseline and after 8-weeks intervention. |
| gait analysis by medical staff | 8weeks | Evaluation using total score of gait analysis by medical staff (-48\ 48).Calculating difference of these score between at baseline and after 8-weeks intervention. |
| Adverse event assessment | 8weeks | A frequency counting of the adverse events. LLT code will be assigned to the reported adverse event using the MedDRA dictionary. The origin date of the term until adverse events define the start date of the treatment program(0 week). Also doing a frequency counting of adverse events observed during the the WA trial operation period, but not included in the safety evaluation of the treatment program. |
| Timed up and go test (bere feet) | 8weeks | Measuring the time that patients take to rise from a chair, walk three metres, turn around, walk back to the chair, and sit down . Calculating difference of those measured values between at baseline and after 8-weeks intervention. Targeting for all patients. |
Countries
Japan
Outcome results
None listed